WO2025098422 - MULTI-RECEPTOR CO-AGONIST COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF
National phase entry:
Publication Number
WO/2025/098422
Publication Date
15.05.2025
International Application No.
PCT/CN2024/130410
International Filing Date
07.11.2024
Title **
[English]
MULTI-RECEPTOR CO-AGONIST COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF
[French]
COMPOSÉ CO-AGONISTE MULTI-RÉCEPTEUR, SON PROCÉDÉ DE PRÉPARATION ET SON UTILISATION
[Chinese]
多重受体共激动剂化合物及其制备方法与应用
Applicants **
SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD
Inventors
XU, Wenjie
LIAN, Xiaolei
XING, Wei
YAN, Jie
CAO, Dapeng
ZHU, Ruihua
ZHANG, Shu
HUA, Huaijie
XIAO, Ying
LI, Qinze
Priority Data
202311479963.X
07.11.2023
CN
202311479746.0
07.11.2023
CN
202411266275.X
10.09.2024
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 1720 | |
| EPO | Filing, Examination, Granting | 11745 | |
| Japan | Filing, Examination, Granting | 1953 | |
| South Korea | Filing, Examination, Granting | 1719 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
21,877
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present invention belongs to the technical field of therapeutic peptides, and relates to a compound represented by general formula (I), or a racemate thereof, or an isomer thereof, or a pharmaceutically acceptable salt thereof, as a multi-receptor co-agonist compound, and use thereof in treating diseases.[French]
La présente invention relève du domaine technique des peptides thérapeutiques, et concerne un composé représenté par la formule générale (I), ou un racémate de celui-ci, ou un isomère de celui-ci, ou un sel pharmaceutiquement acceptable de celui-ci, en tant que composé co-agoniste multi-récepteur, et son utilisation dans le traitement de maladies.[Chinese]
属于治疗性肽技术领域，涉及一种通式(I)所示的化合物，或其消旋体、或其异构体、或其可药用的盐，作为多重受体共激动剂化合物，以及使用其治疗疾病的用途。